VISEN Pharmaceuticals (HK:2561)
:2561
Top Page
VISEN Pharmaceuticals
(2561)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$39.00
▲(15.80% Upside)
Action:ReiteratedDate:12/03/25
VISEN Pharmaceuticals faces significant financial challenges, with ongoing losses and cash flow issues despite revenue growth. Technical indicators suggest a bearish trend, and valuation metrics are unfavorable due to the lack of profitability. These factors collectively result in a low overall stock score.
Positive Factors
Revenue Growth
The company's ability to achieve positive revenue growth indicates successful market penetration and product acceptance, which is crucial for long-term sustainability.
Negative Factors
Profitability Challenges
Ongoing profitability challenges can hinder reinvestment in R&D and limit competitive positioning, affecting long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The company's ability to achieve positive revenue growth indicates successful market penetration and product acceptance, which is crucial for long-term sustainability.
Read all positive factors
VISEN Pharmaceuticals (2561) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.85B
Dividend YieldN/A
Average Volume (3M)37.57K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees58
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,926,865
10 Day Avg. Volume36,930
30 Day Avg. Volume37,566
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)25.08
Price to Sales (P/S)2178.79
P/FCF Ratio-42.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VISEN Pharmaceuticals Business Overview & Revenue Model
Company Description
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People's Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acti...
How the Company Makes Money
VISEN Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications for various diseases. The company’s revenue model is based on direct sales to healthcare providers, hospitals...
VISEN Pharmaceuticals Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | -1.81M | 2.78M | -1.67M | -2.30M |
| Gross Profit | -1.81M | 2.78M | -1.67M | -2.30M |
| EBITDA | -205.16M | -177.62M | -242.26M | -280.95M |
| Net Income | -216.79M | -182.24M | -249.57M | -288.97M |
Balance Sheet | ||||
| Total Assets | 893.36M | 293.82M | 443.80M | 741.27M |
| Cash, Cash Equivalents and Short-Term Investments | 805.91M | 203.59M | 347.78M | 626.46M |
| Total Debt | 1.20M | 2.36M | 3.65M | 6.00M |
| Total Liabilities | 37.81M | 52.55M | 52.92M | 88.67M |
| Stockholders Equity | 855.55M | 241.28M | 390.88M | 652.61M |
Cash Flow | ||||
| Free Cash Flow | -180.36M | -140.97M | -271.83M | -248.31M |
| Operating Cash Flow | -180.24M | -140.86M | -271.31M | -246.55M |
| Investing Cash Flow | 9.12M | -117.00K | -520.00K | -1.77M |
| Financing Cash Flow | 700.54M | -3.09M | -6.95M | -7.95M |
VISEN Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
52 Neutral | HK$1.69B | 117.78 | 0.48% | 0.49% | -0.55% | 45.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$2.37B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$2.85B | -12.37 | -26.24% | ― | ― | ― | |
41 Neutral | HK$724.37M | -4.03 | -9.19% | ― | -30.60% | 28.61% |
* Healthcare Sector Average
HK:2561
VISEN Pharmaceuticals
25.00
-16.40
-39.61%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.99
3.41
215.82%
HK:2216
Broncus Holding Corp.
1.37
0.40
41.24%
HK:2361
Sinohealth Holdings Ltd.
5.06
2.02
66.45%
HK:3681
SinoMab Bioscience Ltd.
1.72
0.53
44.54%
HK:3886
Town Health International Medical Group Ltd.
0.25
0.02
6.38%
VISEN Pharmaceuticals Corporate Events
VISEN Wins China Approval for Once-Weekly Growth Hormone Drug SKYTROFA
Jan 26, 2026
VISEN Pharmaceuticals has received approval from China’s National Medical Products Administration for its biologics license application for lonapegsomatropin (SKYTROFA), a once-weekly growth hormone replacement therapy for children and adole...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.